FOLH1 and neoplasm: Additionally, the results of both TheraP and VISION suggested patients with higher whole-body tumour mean SUV on PSMA PET (SUVmean ≥ 10) were more likely to derive imaging-based PFS benefit from treatment with 177Lu-PSMA-617 than those with lower SUVmean, although all subgroups benefitted [36,37].